Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13732997 | 0.90 | CYP4F2 (0.36) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL232993 | 0.83 | GAA (0.55) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL2048261 | 0.82 | GAA (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11455507 | 0.79 | ALDH1A1 (0.41) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL11140647 | 0.79 | GAA (0.39) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10818981 | 0.79 | TSHR (0.42) | GAAALDH1A1PKMHSD17B10MAPT | |
| SCHEMBL7668564 | 0.79 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL10447420 | 0.79 | GAA (0.50) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL4996013 | 0.77 | GAA (0.48) | GAAMGAMSIMGAM2ALDH1A1 | |
| SCHEMBL28361671 | 0.77 | GAA (0.36) | GAAMGAMSIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487492-B2 | Dibenzothiazepine derivatives and their use in the treatment of CNS disorders | NUMEDICUS LIMITED (GB) | 2016-11-08 | — | — | US | disclosed |
| EP-2699559-B1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LTD (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2014-08-28 | — | — | US | disclosed |
| CN-103717583-A | Dibenzothiazepine derivatives and their use in the treatment of cns disorders | NUMEDICUS LTD | 2014-04-09 | — | — | CN | disclosed |
| EP-2699559-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | Numedicus Limited (GB) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143703-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | NUMEDICUS LIMITED (GB) | 2012-10-26 | — | — | WO | disclosed |
| US-5128359-A | Benzimidazole and azabenzimidazole derivatives which are thromboxane receptor antagonists, their methods of preparation | LABORATOIRES UPSA (FR) | 1992-07-07 | — | — | US | disclosed |
| US-5124336-A | Cardiovascular disorders | LABORATOIRES UPSA (FR) | 1992-06-23 | — | — | US | disclosed |
| US-4701539-A | 3,4-dihydro-4,4-dimethyl-2H-pyran-2-one, an insecticide intermediate | FMC CORPORATION (US) | 1987-10-20 | — | — | US | disclosed |
| US-4473701-A | Lower alkyl 5-chloro-3,3-dimethyl-5-phenylthiopentanoates useful as insecticide intermediates | FMC CORPORATION (US) | 1984-09-25 | — | — | US | disclosed |
| US-4387233-A | Derivatives of 2H-pyran-2-one | FMC CORPORATION (US) | 1983-06-07 | — | — | US | disclosed |
| US-4344884-A | Process for producing cis-3-(2,2-disubstituted-ethenyl)-2,2-dimethylcyclopropanecarboxylic acid and intermediates | FMC CORPORATION (US) | 1982-08-17 | — | — | US | disclosed |
| US-4342694-A | Processes for producing pyrethroid insecticide intermediates | FMC CORPORATION (US) | 1982-08-03 | — | — | US | disclosed |
| US-4235780-A | Derivatives of 2H-pyran-2-one | FMC CORPORATION (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243317-A1 | DIBENZOTHIAZEPINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SLC6A3, DRD1, AVPR2 | GAA 2990/4885MGAM 3053/4885SI 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.